Outlook Therapeutics Inc (NASDAQ: OTLK)’s stock price has decreased by -1.39 compared to its previous closing price of 8.63. However, the company has seen a 9.31% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-21 that Oncobiologics (OTLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is It Worth Investing in Outlook Therapeutics Inc (NASDAQ: OTLK) Right Now?
The stock has a 36-month beta value of 0.00. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OTLK is 7.40M, and at present, short sellers hold a 7.87% of that float. On March 26, 2024, the average trading volume of OTLK was 506.68K shares.
OTLK’s Market Performance
The stock of Outlook Therapeutics Inc (OTLK) has seen a 9.31% increase in the past week, with a -2.99% drop in the past month, and a -0.56% fall in the past quarter. The volatility ratio for the week is 18.04%, and the volatility levels for the past 30 days are at 15.68% for OTLK. The simple moving average for the past 20 days is 8.47% for OTLK’s stock, with a -42.59% simple moving average for the past 200 days.
Analysts’ Opinion of OTLK
Many brokerage firms have already submitted their reports for OTLK stocks, with Chardan Capital Markets repeating the rating for OTLK by listing it as a “Buy.” The predicted price for OTLK in the upcoming period, according to Chardan Capital Markets is $3 based on the research report published on February 15, 2024 of the current year 2024.
CapitalOne gave a rating of “Overweight” to OTLK, setting the target price at $5 in the report published on December 27th of the previous year.
OTLK Trading at 6.27% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.04% of loss for the given period.
Volatility was left at 15.68%, however, over the last 30 days, the volatility rate increased by 18.04%, as shares sank -5.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.21% upper at present.
During the last 5 trading sessions, OTLK rose by +9.31%, which changed the moving average for the period of 200-days by -77.49% in comparison to the 20-day moving average, which settled at $7.82. In addition, Outlook Therapeutics Inc saw 7.99% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OTLK starting from Evanson Jeff, who purchase 62,484 shares at the price of $0.42 back on Mar 07 ’24. After this action, Evanson Jeff now owns 808,459 shares of Outlook Therapeutics Inc, valued at $26,243 using the latest closing price.
Dagnon Terry, the Chief Operations Officer of Outlook Therapeutics Inc, sale 520,000 shares at $1.14 during a trade that took place back on Apr 20 ’23, which means that Dagnon Terry is holding 653,058 shares at $590,200 based on the most recent closing price.
Stock Fundamentals for OTLK
The total capital return value is set at 1.97. Equity return is now at value -827.71, with -122.07 for asset returns.
Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated 3.0 points at debt to capital in total, while cash flow to debt ratio is standing at -1.29. The debt to equity ratio resting at -1.5. The interest coverage ratio of the stock is -0.0.
Currently, EBITDA for the company is -52.6 million with net debt to EBITDA at -0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.44.
Conclusion
To sum up, Outlook Therapeutics Inc (OTLK) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
